L-ASPARAGINASE INDUCED HYPOFIBRINOGENEMIA: A CASE REPORT

Balaji O; Amita d; Navin P

doi:10.22159/ajpcr.2017.v10i5.17320

Authors

Balaji O Post graduate , Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.
Amita d Post graduate , Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.
Navin P Assistant professor, Department of Pharmacology, Kasturba Medical college , Manipal university , Manipal.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i5.17320

Keywords:

L-asparaginase, Hypofibrinogenemia, Adverse effect, Leukemia

Abstract

Anticancer therapy is always known to cause various side effects. L-asparaginase used in the treatment of adult T-cell lymphoblastic leukemia is a
novel class of drug, an enzyme produced from plants as well as microorganisms except human. It is known to cause various adverse reactions including life-threatening neurological complications and thrombotic disorders. Hence, we report a case of hypofibrinogenemia associated with L-asparaginase in a patient treated for T-cell adult lymphoblastic leukemia.

Â

Downloads

Download data is not yet available.

References

Thandeeswaran M, Mahendran R, Kiran K, Nawa K, Palaniswamy M, Jayaraman A. Screening and production of anticarcinogenic enzyme from Escherichia coli CTLS20: L - Asparaginase. Int J Pharm Pharm Sci 2016;8(3):244-8.

Kumar R, Sedolkar V, Triveni A, Kumar M, Shivannavar C, Gaddad S. Isolation, screening and characterization of L-asparaginase producing fungi from medicinal plants. Int J Pharm Pharm Sci 2015;8(1):281-3.

Batool T, Makky EA, Jalal M, Yusoff MM. A comprehensive review on L-asparaginase and its applications. Appl Biochem Biotechnol 2016;178(5):900-23.

Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, et al. The rare coagulation disorders - Review with guidelines for management from the United Kingdom Haemophilia Centre Doctorsâ€™ Organisation. Haemophilia 2004;10(5):593-628.

Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001;114(2):249-57.

Besser MW, MacDonald SG. Acquired hypofibrinogenemia: Current perspectives. J Blood Med 2016;7:217-25.

Bettigole RE, Himelstein ES, Oettgen HF, Clifford GO. Hypofibrinogenemia due to L-asparaginase: Studies of fibrinogen survival using autologous 131-I-fibrinogen. Blood 1970;35(2):195-200.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49(9):2229-32.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27(6):538.